江苏无锡生物医药产业专项母基金招GP

Core Viewpoint - The Jiangsu Wuxi Biopharmaceutical Industry Special Fund aims to promote the development of strategic emerging industries in Jiangsu Province, with a total scale of 4 billion yuan [1]. Group 1: Fund Structure and Investment Strategy - The fund is established in collaboration with Wuxi City to support the integration and development of strategic emerging industry clusters [1]. - Investment methods include setting up sub-funds or direct project investments, with direct investments generally not exceeding 30% of the actual investment amount of the special fund [1]. - The special fund's contribution to sub-funds will not exceed 30% of the sub-fund's total size, and investments in individual direct projects will not exceed 20% of the total paid-in capital of the special fund [1]. Group 2: Investment Focus Areas - The fund primarily invests in pharmaceuticals (including innovative drugs, high-end raw materials, traditional Chinese medicine, cell gene therapy, synthetic biology, etc.), medical devices (including in vitro diagnostic reagents and supporting instruments), and supportive medical industries (including research instruments, synthetic biology, CXO, new medical infrastructure, MAH platform companies, etc.) [2]. - Additional focus areas include consumer healthcare and improving national health quality (including health management, medical aesthetics, special medical foods, and functional foods), as well as AI in pharmaceuticals [2].